Medical Drugs News | Medical XPRT

Showcase

BOC Sciences Becomes the Largest PseudoUridine Supplier in the World

BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world. Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has ...

Sep. 16, 2021

By BOC Sciences

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...

Sep. 9, 2021

By Boehringer Ingelheim Vetmedica, Inc.

Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research

Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...

Sep. 1, 2021

By Creative Biolabs

Recruitment of the smallest infants in the Connection study paused

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

Aug. 25, 2021

By Infant Bacterial Therapeutics AB

Indee Labs Awarded Grant from the National Institute of Allergy & Infectious Disease

Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. ...

Aug. 24, 2021

By Indee Labs

Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China

As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...

Aug. 23, 2021

By Lonza Group Ltd

Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China

As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...

Aug. 23, 2021

By Lonza Group Ltd

Creative Proteomics Announces the Launch of Its New Metabolomics Division

Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...

Aug. 23, 2021

By Creative Proteomics

MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics ...

Aug. 19, 2021

By CD Genomics

CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC

CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully supports customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, ...

Aug. 19, 2021

By CD Genomics

Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company ...

Aug. 18, 2021

By Creative Proteomics

Creative Proteomics Accelerates Life Science Research Through Mass Spectrometry Platform

Creative Proteomics, experienced proteomics, metabolomics, and bioinformatics services supplier, has been well equipped with advanced technologies to meet the increasing needs of researchers and scientists in their proteomics and metabolomics related researches. In the past few years, the technology of mass spectrometry has been greatly developed and their applications broadened. Based on more ...

Aug. 17, 2021

By Creative Proteomics

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Thursday, August 19 at 8:00 am ET. Vered Caplan, CEO of Orgenesis, will be hosting the presentation and answering questions from investors. To access the live presentation, please use the ...

Aug. 12, 2021

By Orgenesis

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...

Aug. 12, 2021

By Biocardia, Inc.

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy

Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, ...

Aug. 12, 2021

By Lonza Group Ltd

Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an ...

Aug. 10, 2021

By Second Genome Therapeutics

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...

Aug. 5, 2021

By Second Genome Therapeutics

Can CBD Help you Sleep?

Can CBD Help You Sleep? For many years now, individuals have turned to CBD for its possible health advantages, but countless people are still asking a very common question: can CBD help you sleep? The short answer is yes, but there is still much to be learned about the process. In the last few years alone, scientists have made great strides in discovering more information about how CBD ...

Jul. 26, 2021

By Medcbdx

Creative Proteomics Launches Complete Product Portfolio for Lipidomics Research Solutions

Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population ...

Jul. 23, 2021

By Creative Proteomics

Creative Proteomics Announces the Launch of Its New Metabolomics Division

Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...

Jul. 23, 2021

By Creative Proteomics